Fernanda Viana Cabral, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Photochemotherapy | 12 | 2024 | 830 | 3.460 |
Why?
|
Leishmania | 7 | 2024 | 75 | 2.300 |
Why?
|
Leishmaniasis, Cutaneous | 7 | 2024 | 137 | 1.970 |
Why?
|
Photosensitizing Agents | 8 | 2024 | 630 | 1.740 |
Why?
|
Singlet Oxygen | 1 | 2024 | 58 | 0.930 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2024 | 395 | 0.840 |
Why?
|
Antiprotozoal Agents | 3 | 2024 | 95 | 0.790 |
Why?
|
Biofilms | 2 | 2024 | 634 | 0.740 |
Why?
|
Methylene Blue | 5 | 2023 | 156 | 0.720 |
Why?
|
Materials Testing | 1 | 2024 | 873 | 0.720 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2024 | 591 | 0.670 |
Why?
|
Microbial Sensitivity Tests | 1 | 2024 | 1967 | 0.580 |
Why?
|
Anti-Infective Agents | 2 | 2023 | 984 | 0.480 |
Why?
|
Leishmania mexicana | 1 | 2023 | 33 | 0.450 |
Why?
|
Phosphorylcholine | 1 | 2024 | 153 | 0.440 |
Why?
|
Mice, Inbred BALB C | 5 | 2024 | 6232 | 0.440 |
Why?
|
Anthraquinones | 2 | 2023 | 41 | 0.430 |
Why?
|
Sporothrix | 1 | 2022 | 3 | 0.420 |
Why?
|
Sporotrichosis | 1 | 2022 | 3 | 0.420 |
Why?
|
Tinea | 1 | 2021 | 13 | 0.390 |
Why?
|
Cat Diseases | 1 | 2021 | 32 | 0.390 |
Why?
|
Metalloporphyrins | 1 | 2021 | 41 | 0.370 |
Why?
|
Dog Diseases | 1 | 2021 | 143 | 0.360 |
Why?
|
Chitosan | 1 | 2021 | 141 | 0.330 |
Why?
|
Antiparasitic Agents | 1 | 2019 | 42 | 0.320 |
Why?
|
Candida albicans | 1 | 2022 | 375 | 0.310 |
Why?
|
Drug Resistance | 1 | 2024 | 1599 | 0.300 |
Why?
|
Zinc | 1 | 2021 | 677 | 0.270 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7478 | 0.250 |
Why?
|
Light | 1 | 2021 | 1355 | 0.240 |
Why?
|
Gamma Rays | 1 | 2016 | 319 | 0.240 |
Why?
|
Antineoplastic Protocols | 1 | 2024 | 48 | 0.230 |
Why?
|
Bandages | 1 | 2024 | 273 | 0.200 |
Why?
|
Nitric Oxide | 1 | 2021 | 2149 | 0.200 |
Why?
|
Wound Healing | 1 | 2022 | 2815 | 0.190 |
Why?
|
Cats | 2 | 2022 | 978 | 0.180 |
Why?
|
Particle Size | 1 | 2024 | 1652 | 0.170 |
Why?
|
Macrophages | 2 | 2024 | 5801 | 0.170 |
Why?
|
Fibroblasts | 2 | 2019 | 4179 | 0.160 |
Why?
|
Nanoparticles | 1 | 2021 | 1989 | 0.160 |
Why?
|
Cell Death | 1 | 2024 | 1682 | 0.150 |
Why?
|
Pseudomonas aeruginosa | 1 | 2024 | 1276 | 0.130 |
Why?
|
Biocompatible Materials | 1 | 2024 | 1703 | 0.130 |
Why?
|
Neoplasms | 1 | 2024 | 22389 | 0.120 |
Why?
|
Reactive Oxygen Species | 2 | 2023 | 2149 | 0.110 |
Why?
|
Itraconazole | 1 | 2022 | 43 | 0.100 |
Why?
|
Drug Delivery Systems | 1 | 2024 | 2238 | 0.100 |
Why?
|
Microsporum | 1 | 2021 | 7 | 0.100 |
Why?
|
Animals | 9 | 2024 | 169335 | 0.090 |
Why?
|
Parasitic Sensitivity Tests | 1 | 2021 | 90 | 0.090 |
Why?
|
Candida | 1 | 2022 | 173 | 0.090 |
Why?
|
Rubiaceae | 1 | 2019 | 3 | 0.080 |
Why?
|
Luminescence | 1 | 2019 | 108 | 0.080 |
Why?
|
Administration, Topical | 1 | 2021 | 704 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5342 | 0.080 |
Why?
|
Mice | 5 | 2024 | 82072 | 0.070 |
Why?
|
Antifungal Agents | 1 | 2022 | 761 | 0.070 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2019 | 945 | 0.070 |
Why?
|
Dogs | 1 | 2021 | 3845 | 0.070 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2019 | 1340 | 0.060 |
Why?
|
Skin | 1 | 2022 | 4506 | 0.040 |
Why?
|
Cell Cycle | 1 | 2016 | 2937 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10765 | 0.040 |
Why?
|
Cell Survival | 1 | 2016 | 5793 | 0.030 |
Why?
|
Databases, Factual | 1 | 2021 | 8094 | 0.030 |
Why?
|
Humans | 6 | 2024 | 768970 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2019 | 19023 | 0.030 |
Why?
|
Apoptosis | 1 | 2019 | 9527 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18354 | 0.020 |
Why?
|
Quality of Life | 1 | 2022 | 13510 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2016 | 10486 | 0.020 |
Why?
|
Infant | 1 | 2022 | 36556 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39394 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 17173 | 0.020 |
Why?
|
Female | 3 | 2024 | 397515 | 0.020 |
Why?
|
Male | 2 | 2022 | 365203 | 0.010 |
Why?
|